Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults (DIA-AID2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01103284|
Recruitment Status : Completed
First Posted : April 14, 2010
Results First Posted : May 26, 2016
Last Update Posted : May 26, 2016
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin. DiaPep277 is a peptide that changes the way the immune system behaves, stopping its attack on the beta-cells.
Adults (>20 years) with newly diagnosed (<6 months) type 1 diabetes will be treated with 10 injections of DiaPep277 or Placebo over a 2-year treatment and follow-up period.
|Condition or disease||Intervention/treatment||Phase|
|Type 1 Diabetes Mellitus||Drug: DiaPep277 Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||475 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||October 2014|
|Actual Study Completion Date :||October 2014|
Administration of 1 mg DiaPep277®, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
1.0 mg dose in 0.5 mL of solution
Placebo Comparator: Placebo
Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
40 mg mannitol in 0.5 mL of solution.
Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months
- Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months [ Time Frame: Baseline and 24 months ]Change in Beta-cell function, measured as stimulated C-peptide secretion 0, 2, 6, 10 and 20 minutes post administration [area under the curve (AUC), 0-20 minutes] at baseline and 24 months, during a glucagon stimulation test (GST). The change in AUC was calculated per patient by subtracting the baseline AUC from the 24 month AUC.
- Percentage of Subjects That Achieve Good Glycemic Control: HbA1c<7% [ Time Frame: 24 and 25 months ]The percentage of subjects achieving good glycemic control, i.e. an HbA1c <7% at study end (Month 25). If HbA1c was missing at Month 25, but the Month 24 value was available, then the Month 24 value was used to calculate the percentage of subjects with an HbA1c ≤ 7% at study end.
- Frequency of Hypoglycemic Events [ Time Frame: Baseline to 25 Months ]Total number of days with at least one hypoglycemic event recorded
- Mean Number of Days With at Least One Hypoglycemic Event [ Time Frame: Baseline to 25 months ]
- Percentage of Subjects Requiring a Daily Insulin Dose ≤ 0.5 IU/kg at End of Study [ Time Frame: 24 and 25 months ]Percentage of subjects requiring a daily insulin dose ≤ 0.5 IU/kg at end of study (25 Months). If insulin dose was missing at Month 25, but the Month 24 value was available, then the Month 24 value was used to calculate the percentage of subjects with a daily insulin dose ≤ 0.5 IU/kg at study end.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01103284
Show 75 Study Locations
|Principal Investigator:||Itamar Raz, MD||Hadassah Medical Center, Jerusalem|
|Principal Investigator:||Thomas Linn, MD||University of Giessen|
|Principal Investigator:||Paolo P Pozzilli, MB, BS, MD||University Campus Bio-Medico, Rome|
|Principal Investigator:||Philip Raskin, MD||UT Southwestern Medical Center, Dallas|